Ann: Following Extension of Survival, PAA Prepares Phase 3 Trial, page-33

Agreed, and the funds would be better spent on Stage two cancer trials Covid trials and point 4) here

● PharmAust identifies optimum monepantel (MPL) drug plasma range for treatment of
pet dogs with B cell lymphoma
● Retrospective data analysis of the phase 2 trial shows the combination of MPL +
prednisolone more than doubling life expectancy of pet dogs compared with standardof-care (prednisolone alone2)
● With the prohibitive pricing of canine chemotherapy PharmAust believes that subject to
phase 3 results, MPL could be commercially compelling
● PharmAust will seek input for the phase 3 trial from potential licensing partners
● Further benefit of the MPL combination treatment was pet owners reported very high
quality of life for their dogs
● PharmAust is planning for additional phase 3 trial sites in New Zealand and the US

If PAA can put some more runs on the board everything else will follow.

All that aside. Great Announcement. Starting to feel like we are starting to get some traction.